


PRELIMINARY PROGRAM




**The 2nd International Conference
'Notch Targeting in Cancer'
Santa Marina Hotel, Mykonos, Greece
27- 29 June 2012**

Information and registration

www.cancerconferences.org

agamemnon@epenetos.com

WE ARE GRATEFUL TO OUR SPONSORS FOR THEIR SUPPORT



Trojantec

Wednesday 27th June 2012

4.00-4.30pm Registration

SESSION 1 Chairman: Charles Coombes

4.30-4.50 Agamemnon Epenetos, ICL, UK

Highlights of the 1st Meeting, Notch Targeting in Cancer, June, 2011

4.50- 5.10 Gunter Merdes, Zurich, CH

Notch signaling: A Systems Biology Approach

5.10-5.30 Gerhardt Holger, CRUK, London, UK

Endothelial Notch signalling dynamics and the regulation of angiogenesis in normal and tumour environment

5.30-5.50 Maggie J Dallman, ICL, UK

Notch signaling in the peripheral immune system

5.50- 6.10 Giannino Del Sal , LNCIB , Trieste, Italy

Escaping tumor suppressor barriers: a Notch/Pin1 axis in breast cancer.

20.00- 22.00
Welcome Reception Cocktail

Thursday 28th June 2012

SESSION 2 Chairman: Ronan O'Hagan

9.00-9.20 Adrian Harris, Churchill Hospital, Oxford, UK

Role of notch signaling and hypoxia induced metabolism in resistance to anti-angiogenic therapy

9.20-9.40 Jan Kitajewski, Columbia University, USA

Targeting tumor angiogenesis with Notch ligand inhibitors

9.40-10.00 Clodia Osipo, Loyola University Medical Center, USA

NOTCH-1 and NOTCH-4 are novel gene targets of PEA3 in breast cancer: novel therapeutic implications.

10.00-10.20 Cigdem Ercan, Mark Vooijs, Maastricht University, The Netherlands

Notch Inhibition induces growth arrest in lobular breast cancer (pre-clinical and clinical)

10.20-11.00 Coffee break and Poster review

SESSION 3 Chairman: Robert Clarke

11.00-11.20 Arijan Groot, Maastricht University, The Netherlands

Mechanism of Notch 3 receptor proteolysis and activity

11.20-11.40 Robert Clarke ,University of Manchester,UK

Roles of Notch receptors and their inhibitors in breast cancer stem cells

11.40-12.00 Keith Brennan, University of Manchester , UK

Developing an in vivo model for CBF1/RBPjk-dependent transformation of breast epithelial cells

12.00-12.20 Freddy Radtke Identification and preclinical validation of novel Notch signaling inhibitors for cancer therapy.

12.20-12.40 Ronan O'Hagan, Merck, USA

Antibodies against Notch receptors

1.00-2.00 p.m. Lunch

2.00-3.00 p.m. Open Air workshops:

i)Notch signalling dynamics Gerhardt Holger & Jan Kitajweski

ii) Clinical trials Lucio Miele & Adrian Harris

SESSION 4 Chairman: Aleksandra Filipovic

4.30pm – 4.50 Paolo Dotto, University of Lausanne, Switzerland and Massachusetts General Hospital, USA

Complexities of Notch function in Squamous Cell Carcinoma development

4.50-5.10 Raymond Moellering, Scripps, USA

Chemoproteomic discovery and characterization of Notch transcriptional complex regulatory proteins

5.10-5.30 Spyros Stylianou, Trojantec, Cyprus and UK

Intranuclear targeting of Mastermind

5.30- 5.50 Silvia Colucci, Imperial College London ,UK

Intranuclear targeting of Notch with Monoclonal Antibodies

**20.00-until late
Conference Dinner**

Friday 29th June 2012

SESSION 5 Chairman: Jan Kitajewski

9.00-9.20 Nikos Robakis, MSSM University, USA

γ -secretase-substrate recruiting (γ -SSR) factors: a novel mechanism for substrate selection and processing

9.20-9.40 Bart De Strooper, Leuven University, Belgium

Heterogeneity of the gamma-secretase complexes create opportunities for more selective therapies

9.40-10.00 Ylenia Lombardo, ICL, UK

The role of nicastrin in cancer stem cells and invasion

10.00-10.40 Aleksandra Filipovic, ICL, UK

Can we target breast cancer cell invasiveness using anti-nicestrin monoclonal antibodies in vitro and in vivo?

10.40-11.30 Coffee Break and Poster Review

SESSION 6 Chairman: Adrian Harris

11.30-11.50 Antonio Duarte , IGC, Portugal

Efficacy of DLL4 blockade in murine autochthonous tumour models

11.50-12.20 Lucio Miele, National Cancer Institute and Mississippi Cancer Centre, USA

- a) Final results of a clinical trial
- b) Triple Negative Breast Cancer , Endocrine resistance and non-canonical Notch signaling

12.20-12.50 Charles Coombes, ICL, UK

Targeting Notch in Breast Cancer: Recent Results

1.00-2.00 Lunch

2.00-3.00 Open Air workshops:

i) Notch signaling dynamics Gerhard Holger & Jan Kitajweski

ii) Clinical trials Lucio Miele & Adrian Harris

SESSION 7 Chairman: Agamemnon Epenetos

4.30-6.00 Open Session Brief presentations selected from submitted abstracts

4.30-4.50 Vincenza Caolo, Maastricht University, the Netherlands,

**ADAMs induce ligand-independent Notch activation during neovascularization:
implications for tumor angiogenesis.**

4.50-5.10 TBA

5.10- 5.30 TBA

5.30-5.50 TBA

6.00 Farewell Agamemnon Epenetos

POSTER PRESENTATIONS

These will be displayed in the Hall area during the whole period of the conference

Information and registration:

www.cancerconferences.org

agamemnon@epenetos.com

